Edition:
United States

STADA Arzneimittel AG (STAGn.DE)

STAGn.DE on Xetra

81.30EUR
17 Aug 2018
Change (% chg)

€0.20 (+0.25%)
Prev Close
€81.10
Open
€81.28
Day's High
€81.66
Day's Low
€80.86
Volume
25,167
Avg. Vol
43,071
52-wk High
€90.24
52-wk Low
€65.03

Latest Key Developments (Source: Significant Developments)

STADA Arzneimittel: Consent Solicitation For Euro Bond 2015/2022
Friday, 8 Jun 2018 09:00am EDT 

June 8 (Reuters) - STADA Arzneimittel AG ::CONSENT SOLICITATION FOR STADA EURO BOND 2015/2022.ALSO INTENDS TO OFFER TO ACQUIRE STADA 2015 NOTES AT PAR PLUS ACCRUED INTEREST.  Full Article

STADA Arzneimittel: Domination And Profit And Loss Transfer Agreement Takes Effect
Tuesday, 20 Mar 2018 06:48am EDT 

March 20 (Reuters) - STADA ARZNEIMITTEL AG ::DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH TAKES EFFECT / BEGINNING OF ACCEPTANCE PERIOD FOR SEVERANCE OFFER.  Full Article

STADA to propose a dividend of 0.11 euros per share
Thursday, 8 Mar 2018 03:41am EST 

March 8 (Reuters) - Stada Arzneimittel Ag ::DGAP-ADHOC: STADA: EXECUTIVE BOARD AND SUPERVISORY BOARD OF STADA ARZNEIMITTEL AG RESOLVE ON A PROPOSAL FOR THE APPROPRIATION OF PROFITS AND PROPOSE A DIVIDEND IN THE AMOUNT OF EUR0.11 PER SHARE.  Full Article

Stada FY Net Income Down By 1 Pct At EUR 85.3 Mln
Thursday, 8 Mar 2018 03:34am EST 

March 8 (Reuters) - Stada ::GROUP SALES INCREASED IN 2017 FINANCIAL YEAR BY 8% TO EUR2,313.9M.‍POSITIVE OUTLOOK FOR 2018​.REPORTED EBITDA INCREASED IN 2017 BY 1% TO EUR363.8M.REPORTED NET INCOME REDUCED IN 2017 FINANCIAL YEAR BY 1% TO EUR85.3M.‍SUGGEST TO PAY A DIVIDEND FOR 2017 FINANCIAL YEAR OF EUR0.11 PER STADA SHARE​.OUTLOOK 2018: GROUP SALES ADJUSTED FOR CURRENCY AND PORTFOLIO EFFECTS ARE EXPECTED TO BE EUR2.495BN +/- 5%.OUTLOOK 2018: ADJUSTED EBITDA IS EXPECTED TO BE EUR480M +/- 5% AND ADJUSTED NET INCOME EUR230M +/- 5%.‍FOR 2019, EXECUTIVE BOARD EXPECTS TO BE ABLE TO ACHIEVE ADJUSTED GROUP SALES OF EUR2.575BN +/- 5%​.‍FOR 2019 EXPECTS TO BE ABLE TO ACHIEVE ADJUSTED EBITDA OF EUR540M +/- 5% AND ADJUSTED NET INCOME OF EUR275M +/- 5%​.  Full Article

Stada Says EMA Starts Evaluation Of Resubmitted Pegfilgrastim Application
Friday, 2 Mar 2018 03:33am EST 

March 2 (Reuters) - Stada ::DGAP-NEWS: STADA ARZNEIMITTEL AG: EMA STARTED THE EVALUATION OF RESUBMITTED MARKETING AUTHORISATION APPLICATION FOR BIOSIMILAR PEGFILGRASTIM.‍EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED REGULATORY RESUBMISSION OF ITS PROPOSED BIOSIMILAR TO AMGEN'S NEULASTA​.  Full Article

STADA To Appoint Novartis Exec Goldschmidt As New CEO - Apotheke Adhoc
Thursday, 1 Feb 2018 01:31am EST 

Feb 1 (Reuters) - Stada ::TO APPOINT NOVARTIS EXECUTIVE PETER GOLDSCHMIDT AS NEW CEO - REPORT BY APOTHEKE ADHOC.STADA NOT IMMEDIATELY AVAILABLE FOR COMMENT.  Full Article

Stada Says Domination And Profit And Loss Transfer Agreement Concluded
Tuesday, 19 Dec 2017 12:05pm EST 

Dec 19 (Reuters) - Stada ::DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT PURSUANT TO SECTIONS 291 ET SEQQ. AKTG CONCLUDED BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH.DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT STILL REQUIRES CONSENT OF EXTRAORDINARY GENERAL MEETING OF STADA, WHICH IS PLANNED FOR 2 FEBRUARY 2018.SHAREHOLDERS' MEETING OF NIDDA HEALTHCARE HAS ALREADY CONSENTED TO AGREEMENT ON TODAY'S DATE.NIDDA HEALTHCARE IS OFFERING TO ACQUIRE SHARES OF OUTSIDE STADA SHAREHOLDERS IN RETURN FOR CASH COMPENSATION OF EUR 74.40 PER SHARE.DOMINATION AGREEMENT PROVIDES FOR ANNUAL RECURRING COMPENSATION PAYMENT FOR OUTSIDE SHAREHOLDERS OF EUR 3.82 GROSS PER SHARE.  Full Article

Stada confident domination agreement can be struck in Q1 2018
Thursday, 9 Nov 2017 06:22am EST 

Nov 9 (Reuters) - Stada :CEO say can confirm medium-term targets.CEO says are confident that a profit and domination agreement with Elliott can be concluded at an EGM in Q1 2018.  Full Article

Stada ‍says is on track to achieve targets for 2017
Thursday, 9 Nov 2017 01:30am EST 

Nov 9 (Reuters) - Stada Arzneimittel AG says :Stada shows good business development in the third quarter of 2017 and the first nine months.9M sales 1.698 billion eur.‍Well on track to achieve targets for 2017​.Q3 reported group sales ‍554.8​ million eur.‍Q3 adjusted ebitda 109.8​ million eur.‍Q3 adjusted net income 31.2​ million eur.‍Expects key earnings figures in q4 of 2017 to be lower than corresponding figures in q3 of 2017​.‍2017 group sales adjusted for currency and portfolio effects are expected to be in range of euro 2.280 billion to euro 2.350 billio​.‍Sees 2017 adjusted ebitda between euro 430 million and euro 450 million​.‍Sees 2017 adjusted net income between euro 195 million and euro 205 million​.  Full Article

Stada says elects Guenter von Au as new chairman
Wednesday, 27 Sep 2017 10:49am EDT 

Sept 27 (Reuters) - Stada Arzneimittel Ag :dgap-adhoc: stada arzneimittel ag: supervisory board of stada arzneimittel ag elects dr. Günter von au as new chairman.  Full Article

BRIEF-STADA Says On Track To Meet Targets After Q1 Results

* DGAP-NEWS: STADA ARZNEIMITTEL AG: STADA WITH SOLID BUSINESS DEVELOPMENT IN THE FIRST QUARTER OF 2018